August 29, 2024 07:17 AM EDT
People
R&D

Pre­clin­i­cal team hit hard­est in Re­pare's R&D pri­or­i­ti­za­tion, lay­offs

Katherine Lewin

News Reporter

Re­pare Ther­a­peu­tics is cut­ting its head­count by about 25%, with most of the lay­offs con­cen­trat­ed in the com­pa­ny’s pre­clin­i­cal team, as part of what the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times